Eiki Ichihara

7.2k total citations
153 papers, 2.4k citations indexed

About

Eiki Ichihara is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Eiki Ichihara has authored 153 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 122 papers in Pulmonary and Respiratory Medicine, 108 papers in Oncology and 34 papers in Molecular Biology. Recurrent topics in Eiki Ichihara's work include Lung Cancer Treatments and Mutations (103 papers), Lung Cancer Research Studies (39 papers) and Colorectal Cancer Treatments and Studies (32 papers). Eiki Ichihara is often cited by papers focused on Lung Cancer Treatments and Mutations (103 papers), Lung Cancer Research Studies (39 papers) and Colorectal Cancer Treatments and Studies (32 papers). Eiki Ichihara collaborates with scholars based in Japan, United States and United Kingdom. Eiki Ichihara's co-authors include Katsuyuki Kiura, Nagio Takigawa, Mitsune Tanimoto, Katsuyuki Hotta, Kadoaki Ohashi, Toshio Kubo, Nobuaki Ochi, Masahiro Tabata, Takashi Ninomiya and Daijiro Harada and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Eiki Ichihara

137 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eiki Ichihara Japan	29	1.6k	1.5k	945	395	195	153	2.4k
Alessandro Leonetti Italy	18	1.1k 0.7×	1.2k 0.8×	848 0.9×	424 1.1×	157 0.8×	54	2.0k
Silvia La Monica Italy	32	1.2k 0.7×	1.0k 0.7×	1.1k 1.1×	367 0.9×	155 0.8×	67	2.2k
Shang‐Gin Wu Taiwan	29	1.5k 0.9×	1.9k 1.3×	955 1.0×	683 1.7×	160 0.8×	64	2.6k
Roberta Minari Italy	25	1.5k 0.9×	1.7k 1.1×	1.1k 1.2×	585 1.5×	208 1.1×	66	2.5k
Guanghui Gao China	30	1.5k 0.9×	1.4k 0.9×	811 0.9×	620 1.6×	137 0.7×	86	2.5k
Toshiyuki Kozuki Japan	25	2.0k 1.3×	1.8k 1.2×	725 0.8×	299 0.8×	122 0.6×	113	3.0k
Takehito Shukuya Japan	29	1.4k 0.9×	1.5k 1.0×	610 0.6×	438 1.1×	148 0.8×	130	2.5k
Thanyanan Reungwetwattana Thailand	21	1.1k 0.7×	1.4k 0.9×	571 0.6×	321 0.8×	138 0.7×	72	1.9k
Jin‐Hyoung Kang South Korea	25	1.3k 0.8×	1.3k 0.9×	624 0.7×	418 1.1×	130 0.7×	98	2.2k
Robert Veve United States	10	1.3k 0.8×	1.3k 0.8×	934 1.0×	336 0.9×	122 0.6×	12	2.3k

Countries citing papers authored by Eiki Ichihara

Since Specialization

Citations

This map shows the geographic impact of Eiki Ichihara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eiki Ichihara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eiki Ichihara more than expected).

Fields of papers citing papers by Eiki Ichihara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eiki Ichihara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eiki Ichihara. The network helps show where Eiki Ichihara may publish in the future.

Co-authorship network of co-authors of Eiki Ichihara

This figure shows the co-authorship network connecting the top 25 collaborators of Eiki Ichihara. A scholar is included among the top collaborators of Eiki Ichihara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eiki Ichihara. Eiki Ichihara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sakamoto, Tomohiro, et al.. (2024). EP.11D.02 An Investigator-Initiated Phase II Study of Combination Treatment of Nivolumab and TM5614, A PAI-1 Inhibitor for Previously Treated NSCLC. Journal of Thoracic Oncology. 19(10). S614–S614. 1 indexed citations

Tsuge, Mitsuru, Eiki Ichihara, Kou Hasegawa, et al.. (2024). Increased Oxidative Stress and Decreased Citrulline in Blood Associated with Severe Novel Coronavirus Pneumonia in Adult Patients. International Journal of Molecular Sciences. 25(15). 8370–8370. 1 indexed citations

Morita, Ayako, Eiki Ichihara, Koji Inoue, et al.. (2024). Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non‐small‐cell lung cancer. International Journal of Cancer. 154(9). 1607–1615. 14 indexed citations

Miyake, Noriko, Masami Takeyama, Hideko Isozaki, et al.. (2024). A novel molecular target, superoxide dismutase 1, in ALK inhibitor-resistant lung cancer cells, detected through proteomic analysis. Experimental Cell Research. 442(2). 114266–114266. 1 indexed citations

Yang, James Chih‐Hsin, Jong Seok Lee, Yun Fan, et al.. (2023). Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.. Journal of Clinical Oncology. 41(17_suppl). LBA9000–LBA9000. 50 indexed citations

Kubo, Toshio, Eiki Ichihara, Daijiro Harada, et al.. (2023). Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer. Respiratory Investigation. 61(5). 643–650. 3 indexed citations

Kano, Hirohisa, Eiki Ichihara, Hiromi Watanabe, et al.. (2021). SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1- , or EGFR -altered Non–small Cell Lung Cancer. Molecular Cancer Therapeutics. 20(9). 1653–1662. 13 indexed citations

Ochi, Nobuaki, Eiki Ichihara, Nagio Takigawa, et al.. (2021). The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression. European Journal of Cancer. 149. 73–81. 43 indexed citations

Hara, Naofumi, Eiki Ichihara, Daijiro Harada, et al.. (2021). Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology. 147(12). 3749–3755. 7 indexed citations

10.

Ichihara, Eiki, Daijiro Harada, Koji Inoue, et al.. (2020). Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors. Cancer Immunology Immunotherapy. 70(1). 101–106. 28 indexed citations

11.

Kano, Hirohisa, Eiki Ichihara, Daijiro Harada, et al.. (2020). Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status. Cancer Science. 111(10). 3739–3746. 18 indexed citations

12.

Ichihara, Eiki, Daijiro Harada, Koji Inoue, et al.. (2019). The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. Lung Cancer. 139. 140–145. 74 indexed citations

13.

Ichihara, Eiki, David Westover, Catherine B. Meador, et al.. (2017). SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Research. 77(11). 2990–3000. 104 indexed citations

14.

Taniguchi, Akihiko, Nobuaki Miyahara, Naohiro Oda, et al.. (2017). Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease.. PubMed. 71(5). 453–457. 4 indexed citations

15.

Isozaki, Hideko, Eiki Ichihara, Nagio Takigawa, et al.. (2016). Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. Cancer Research. 76(6). 1506–1516. 109 indexed citations

16.

Saito, Ken, Nagio Takigawa, Naoko Ohtani, et al.. (2013). Antitumor Impact of p14ARF on Gefitinib-Resistant Non–Small Cell Lung Cancers. Molecular Cancer Therapeutics. 12(8). 1616–1628. 12 indexed citations

17.

Shien, Kazuhiko, Shinichi Toyooka, Hiromasa Yamamoto, et al.. (2013). Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells. Cancer Research. 73(10). 3051–3061. 223 indexed citations

18.

Minami, Daisuke, Nagio Takigawa, Minoru Takata, et al.. (2012). Synergistic Effect of Olaparib with Combination of Cisplatin on PTEN -Deficient Lung Cancer Cells. Molecular Cancer Research. 11(2). 140–148. 50 indexed citations

19.

Rai, Kammei, Nagio Takigawa, Sachio Ito, et al.. (2011). Liposomal Delivery of MicroRNA-7–Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells. Molecular Cancer Therapeutics. 10(9). 1720–1727. 110 indexed citations

20.

Ohashi, Kadoaki, Nagio Takigawa, Eiki Ichihara, et al.. (2009). Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice. Cancer Research. 69(17). 7088–7095. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact